Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZT002 Injection on QTc Interval in Chinese Overweight and Obese Subjects
NCT07697846Phase 1Active, not recruiting
- Sponsor
- QL Biopharm
- Start
- Jul 2026
- Primary completion
- Jan 2027
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in obesity and Overweight comparing cohort1 ZT002 injection with cohort2 ZT002 injection matching placebo (2 arms). Primary endpoint: Change to baseline- and placebo-corrected QTc interval. Started Jul 2026; status: active, not recruiting.
02
Drugs
zovaglutide
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT07697846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07697846.